Cargando…
Low‐dose gemcitabine plus nab‐paclitaxel versus standard‐dose gemcitabine plus nab‐paclitaxel in elderly patients with metastatic pancreatic cancer: A randomized Phase II trial
BACKGROUND AND AIM: A multicenter, open‐label randomized Phase II trial was conducted to determine whether low‐dose gemcitabine plus nab‐paclitaxel (GnP) could improve tolerability and show equivalent efficacy to the standard‐dose GnP for elderly patients with metastatic pancreatic cancer. METHODS:...
Autores principales: | Kamata, Ken, Imai, Hajime, Matsumoto, Hisakazu, Yamashita, Yukitaka, Kato, Takao, Nishi, Katsuhisa, Omoto, Shunsuke, Minaga, Kosuke, Yamao, Kentaro, Hyodo, Tomoko, Im, Sung‐Woon, Hara, Akane, Yoshikawa, Tomoe, Ishikawa, Rei, Okamoto, Ayana, Yamazaki, Tomohiro, Nakai, Atsushi, Ueshima, Kazuomi, Chiba, Yasutaka, Takenaka, Mamoru, Watanabe, Tomohiro, Kitano, Masayuki, Kudo, Masatoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wiley Publishing Asia Pty Ltd
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10517437/ https://www.ncbi.nlm.nih.gov/pubmed/37744711 http://dx.doi.org/10.1002/jgh3.12966 |
Ejemplares similares
-
Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
por: Han, Sung Yong, et al.
Publicado: (2020) -
Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
por: Chen, Shuling, et al.
Publicado: (2023) -
Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma
por: Zong, Yuan, et al.
Publicado: (2020) -
Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
por: Rogers, Jane E., et al.
Publicado: (2020) -
Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer
por: Tsujimoto, Akiko, et al.
Publicado: (2019)